Penserra Capital Management’s Nautilus Biotechnolgy NAUT Stock Holding History

Penserra Capital Management’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,175	Closed	-$11K	–	1124
2022 Q2	$11K	Sell	4,175 -536	-11%	-$2K	﹤0.01%	1228
2022 Q1	$20K	Sell	4,711 -1,148	-20%	-$4.71K	﹤0.01%	1254
2021 Q4	$30K	Buy	5,859 +895	+18%	+$4.79K	﹤0.01%	1148
2021 Q3	$30K	Buy	4,964 +210	+4%	+$1.67K	﹤0.01%	1181
2021 Q2	$48K	Sell	4,754 -1,199	-20%	-$13K	﹤0.01%	1012
2021 Q1	$82K	Buy	+5,953	New	+$82.5K	﹤0.01%	718

Other funds holding NAUT

AEPBI

AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

MVG

Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CFM

Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return

ACI

Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return

ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Penserra Capital Management's NAUT Position: Q3 2022 in Review

Penserra Capital Management sold out of Nautilus Biotechnolgy (NAUT) in Q3 2022, closing a stake of 4,175 shares — an estimated $11K sold.

Penserra Capital Management first reported a position in NAUT in Q1 2021 and held it in 6 quarters. The position peaked at $82K in Q1 2021. 86 funds tracked by Wall St. Rank hold NAUT as of Q3 2022.

Penserra Capital Management reported no remaining Nautilus Biotechnolgy position as of Q3 2022 after selling out during the quarter.
Penserra Capital Management sold 4,175 Nautilus Biotechnolgy shares in Q3 2022, an estimated $11K.
Penserra Capital Management first reported a position in Nautilus Biotechnolgy in Q1 2021 and held it in 6 quarters.
Penserra Capital Management's Nautilus Biotechnolgy position peaked at $82K in Q1 2021.
86 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.